|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM179840266 |
| 003 |
DE-627 |
| 005 |
20231223154446.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2008 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2008.03.512
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0600.xml
|
| 035 |
|
|
|a (DE-627)NLM179840266
|
| 035 |
|
|
|a (NLM)18508409
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ullenhag, G J
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55
|
| 264 |
|
1 |
|c 2008
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 03.09.2008
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a We assessed T-cell responses in young osteosarcoma patients vaccinated with 105AD7, 1-6 months after having received chemotherapy. 105AD7 is a human anti-idiotypic antibody mimicking CD55, a glycoprotein that protects from attack by complement and which is overexpressed on osteosarcoma cells. Seven out of 21 investigated patients made a IFN-gamma T-cell response against the vaccine, 105AD7 as assessed by ELISPOT. Cytokine secretion was analysed using Luminex assays and revealed TNF-alpha and GM-CSF responses not only to the vaccine but also towards the native antigen, CD55, in 5 / 14 (36%) of investigated patients. Importantly, the Luminex assay was found to be more sensitive than the more established T-cell assays (ELISPOT and proliferation assay), since responses towards the native antigen were recorded in this assay. Clinical responses and induction of immune responses to both the anti-idiotype and the native CD55 antigen support the use of CD55 as a target in cancer treatment
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Clinical Trial, Phase I
|
| 650 |
|
4 |
|a Clinical Trial, Phase II
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Multicenter Study
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a 105AD7 antibody
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Anti-Idiotypic
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
| 650 |
|
7 |
|a CD55 Antigens
|2 NLM
|
| 650 |
|
7 |
|a Cancer Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Tumor Necrosis Factor-alpha
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 650 |
|
7 |
|a Granulocyte-Macrophage Colony-Stimulating Factor
|2 NLM
|
| 650 |
|
7 |
|a 83869-56-1
|2 NLM
|
| 700 |
1 |
|
|a Spendlove, I
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Watson, N F S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kallmeyer, C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pritchard-Jones, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Durrant, L G
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 128(2008), 2 vom: 15. Aug., Seite 148-54
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:128
|g year:2008
|g number:2
|g day:15
|g month:08
|g pages:148-54
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2008.03.512
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 128
|j 2008
|e 2
|b 15
|c 08
|h 148-54
|